case in a transplant recipient. Cyclophosphamide was used more often in patients without transplants than in the others (46% as against 500 in the first three years), and the excess was more pronounced in those who had received the drug (three cases observed as against 0-29 expected; P <0-01). Two further cases occurred in patients without transplants treated with cyclophosphamide after the latest follow-up date used for this analysis, and several other cases of bladder cancer after cyclophosphamide treatment have been reported elsewhere.18 Hence the risk of this disease is apparently related specifically to the use of cyclophosphamide.
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Of other rare tumours, three were squamous carcinomas of the vulva (one in the non-transplant series), one was a metastasising carcinoid tumour (transplant series), and one was an intrahepatic biliary carcinoma (non-transplant series). The three cancers of the vulva were similar in character to squamous carcinoma of other parts of the skin and are perhaps more appropriately classed with skin cancers than with "other" cancers. The intrahepatic biliary carcinoma in a patient in the non-transplant series is interesting in view of Hoover and Fraumeni's8 report of similar cases in transplant recipients.
Our findings provide no clear evidence that immunosuppressive drugs produce an increased risk of most of the common cancers. Few of the patients, however, had been under observation for over five years, and an increase may appear later. Diseases, 1978, Indomethacin significantly reduced the fall in blood pressure on standing (P <0 001) and lessened or reversed orthostatic symptoms. Furthermore, there was an enhanced response to the cold pressor test and a reduction in forearm blood flow.
These findings suggest that indomethacin has a positive effect on systemic vascular resistance.
Introduction
Orthostatic hypotension is a common, disabling problem in Parkinsonism. The lesion responsible may be localised within the efferent sympathetic fibres of the baroreceptor system,' though other lesions cannot be excluded.' 2 (5-9±0 9 to 5-2±0 87 ml/min/100 ml) (fig 4) . All these changes were statistically significant (see figs 1-4).
Oral indomethacin reduced the fall in mean blood pressure on standing (34 8±4-1 to 17-3±3-5 mm Hg; P<0-001), but placebo had no noticeable effect (fig 2) . Orthostatic symptoms were reduced or reversed by indomethacin, and in no case did indomethacin modify or aggravate Parkinsonism. 
Discussion
We found that indomethacin was highly effective against postural hypotension in patients with idiopathic Parkinsonism. The reduction of forearm blood flow and enhanced bloodpressure response to the cold pressor test suggest that given intravenously the drug causes vascular smooth-muscle constriction both in basal conditions and after neuroadrenergic stimuli.
We cannot explain the effect of indomethacin in raising the peripheral vascular resistance. The drug may, however, inhibit the synthesis of prostaglandins and related substances, some of which are potent vasodilators.6 8 This hypothesis may be the case in Bartter's syndrome, in which the kidney produces excessive amounts of prostaglandins. 9-11 Nevertheless, in normal people and conditions in which excessive synthesis of prostaglandins does not occur a different mechanism of action of indomethacin-that is, independent of prostaglandin metabolism-cannot be a priori excluded.
Summary and conclusions A case-control study was conducted of the deaths from subarachnoid haemorrhage (SAH) in women aged 15-44 in England and Wales in 1976. There was a small excess of oral contraceptive use by the women who died from SAH compared with their generally healthy practicematched controls; this was not, however, statistically significant. Out of 134 women who died from SAH, 34 had a history of hypertension compared with only six of their controls. Renal disease and pre-eclamptic toxaemia were more commonly associated with hypertension in the dead women than in controls.
No change in the annual mortality from SAH has been observed in the past 20 years such as might have been expected if the risks were high. Although current or past use of oral contraceptives may have increased the blood pressure and risk of SAH in a few women, the most Introduction In October 1977 an analysis in the study of oral contraceptives carried out by the Royal College of General Practitioners (RCGP) of deaths among women suggested that there might be a strong association between the use of the "pill" and fatal cerebrovascular disease.' Ten women who had used the pill at any time during the eight years of the study had died compared with only three controls who had never used the pill, and, of these 10 deaths, nine were from subarachnoid haemorrhage (SAH) compared with none of the deaths in the controls. The mortality rates from SAH were estimated to be 9 3 and 15-9/ 100 000 woman-years among current and ex-users of oral contraceptives respectively.
Since perhaps as many as one-third of all women of childbearing age were using oral contraceptives while a further onethird may have used them in the past it would have been expected that such a large risk would have been reflected in the national mortality statistics published by the Office of Population Censuses and Surveys (OPCS) . No such increase in deaths was apparent, and it was therefore decided to conduct a further study of deaths from SAH in the female population of England and Wales.
